DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Response to Amendment
The amendment filed August 4, 2026 has been entered.
Claims 19-30 are pending.
Applicant’s submission of new drawings partially ameliorate the objection to the Drawings.
Applicant’s arguments are persuasive to obviate objections to the Specification.
Applicant’s arguments and amendments partially ameliorate the rejection to the claims under 35 U.S.C. 112(a); an updated rejection is presented in light of Applicant’s amendments.
Applicant’s arguments and amendments obviate rejections to the claims under 35 U.S.C. 112(b) and 103.
Response to Arguments
Drawings
Applicant’s amendments and arguments have been fully considered but they are not persuasive. New axis labels, titles, and legend terminology are not provided with adequate definition in the Specification. Applicant’s substitute Drawings remain objected, with an updated objection presented.
Specification
Applicant’s arguments do not address the issue of the term “AP’s ratio” used in Paragraph 0152; however, Examiner has removed the objection to the incoherent/unclear process defined in Paragraphs 0151-0154 since Applicant identifies that the claimed SFq is “not limited to or defined by the mathematical model of paragraphs [0151]-[0154]” (Remarks dated August 4, 2026, page 9).
35 U.S.C. 112(a)
Applicant has amended the claims to recite diagnosis/association of certain parameters and frequencies with “solid tumors” as opposed to “a cancer.” However, insufficient written support is provided to indicate Applicant had possession of an invention capable of diagnosing/associating parameters for any and all solid tumors.
Regarding enablement, Examiner maintains the position that undue experimentation is required since, in order for the invention to perform diagnosis or association to any class of solid tumor, the difficulty of carrying out the invention is three-fold: 1) the skilled artisan must identify a sufficient number of patients having a differing solid tumor diagnosis sufficient to form separable diagnoses; 2) the skilled artisan must carry out application of low-energy carrier output signals via a particular device and intrabuccally administer such signals to the number of patients identified prior at a non-exposure and exposure period; and 3) perform mathematical processing to identify specific frequency electromagnetic carrier signals, with portions of exemplary processing in Applicant’s Specification (e.g., Paragraphs 0151-0154) being possessed of terms with inadequate definition.
Prior Art Rejections
Applicant’s arguments with respect to the rejection of the claims under 35 U.S.C. 103 have been fully considered and are persuasive. The rejection to each claim under 35 U.S.C. 103 has been withdrawn. Examiner considers Applicant’s argument persuasive in that a significant inventive gap is present in modifying the sleep disorder treatment invention of Chang with the broad physiological signal correlations to cancer types disclosed in Chen.
Drawings
The drawings are objected to because of the following issues:
Fig. 6B: Axes are now labeled “SD1” and “SD2” for each of the four graphs shown; however, the terms “SD1” and “SD2” are not defined in Applicant’s Specification. The legends for each graph are not provided with clear description in Applicant’s Specification. For instance, it is unclear what is meant by “Ft. line for Total.” Applicant’s Paragraph 0116 states “there are a series of plots of physiological responses in responses to reactive and non-reactive pulses for four patients with diagnosis of hepatocellular carcinoma shown.” It is unclear what the phrase “physiological responses” refers to and whether such a phrase intends to refer to hemodynamic parameters.
Fig. 6C: It is unclear what a “reordered frequency variable is.” Applicant’s Paragraph 0118 states “Referring now to FIG. 6C, there are shown plots demonstrating that different health condition-specific SFq can be defined by linear relationships. Health condition-specific SFq from amplitude modulated from 100 Hz to 40,000 Hz are distributed in an apparent chaotic manner in different health conditions. reorganizing different health condition-specific SFq using mathematical calculations described in the invention, we obtain linear equation defined by Hz = a + #3x with R2=99.9%.” This does not provide clarifying information as to what is depicted in Fig. 6C. Applicant states that “different health condition-specific SFq can be defined by linear relationships;” however, relationship to what is not clearly defined.
Fig. 6D: It is unclear how a distribution of SFq (i.e. electromagnetic signals having amplitude modulated frequencies) is calculated in order to be graphed as shown.
Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
WRITTEN DESCRIPTION:
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 19 and dependent claims thereof are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
Re. Claim 19: Claim 19 recites a “system for diagnosing a solid tumor in a patient.“ Applicant’s disclosure is insufficient to support the full scope of the claimed invention.
The sections of the Specification titled “Example 6” (Paragraphs 0120-0124) and “Example 7” (Paragraphs 0125-129) appear to be excerpts from scientific literature naming at least one inventor of the present application, and are directed to using electromagnetic signals to treat breast, ovary, pancreas, and liver cancer. Paragraphs 0131-0154 describe an embodiment of the invention which explicitly discusses diagnosis of at least hepatocellular carcinoma (i.e., a liver cancer) and breast cancer. Paragraph 0149 makes reference to U.S. patent applications and patents which have identified frequencies which are efficacious in characterization, diagnosis, treatment, and frequency discovery of a type of cancer or tumor of a subject; however, these documents are not incorporated by reference, nor is their discussion in Paragraph 0149 supportive of the capability of the invention to diagnose any solid tumor based on hemodynamic response patterns.
Thus, what appears to be claimed is a system which applies one or more specific electromagnetic frequencies (SFq) known to cause a physiological response corresponding to a form cancer, whereby such response is detected via changes in hemodynamic parameters (Hdp) between an SFq application period and non-application period. However, the application identifies only a limited number of frequencies corresponding to a limited number of health states (i.e., exemplary forms of tumors).
In light of the above, Applicant’s disclosure appears to provide support for diagnosis of specific epithelial cancers (i.e., breast, ovarian, pancreatic, and hepatocellular carcinoma). For instance, diagnosis of other solid tumor types such as those found in bone, mesenchymal tissues, or arising from specialized cell lineages such as hematopoietic, neural crest, or melanocytic cells do not appear to be supported by Applicant’s method of identifying a corresponding hemodynamic response pattern.
ENABLEMENT:
Claims 19 and dependent claims thereof are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
Re. Claim 19: Applicant’s disclosure is further not enabling of the full scope of the invention (i.e., a system which is capable of diagnosing any form of solid tumor based on a hemodynamic response patterns). The nature of the invention is directed to, essentially, mathematical correlation of data obtained with a particular electromagnetic probe device. The state of the prior art discloses the concept of correlating sensor data to certain disease states, but does not disclose inventions capable of diagnosing any solid tumor from hemodynamic response patterns. The level of one of ordinary skill in the arts is high - one of ordinary skill in the art would be apprised of statistical techniques described in the Specification; however, the central thrust of the invention is dependent upon accruing sufficient data from a tested population to correlate hemodynamic response patterns (resultant from application of electromagnetic energy via a particular electromagnetic probe device) to specific electromagnetic frequencies in order to identify which frequencies correspond to disease states, which is determined as a “diagnosis.” The determination of the diversity of disease states is dependent on the diversity of disease states in a population tested via this particular device and method. The amount of direction provided by the inventor is insufficient to carry out the full scope of the invention. For instance, Paragraph 0110 states “[t]he patient's diagnosis and the nature of AM RF EMIF exposure (HCC-specific, breast cancer specific, and randomly chosen frequencies) were disclosed before computational analysis in order to constitute a knowledge base.” That is, the specific frequencies (SFq) associated with a particular disease state which are applied to a patient are obtained from a knowledge base created via experimentation. Paragraph 0138 describes forming a knowledge base consisting of patients with hepatocellular carcinoma, breast cancer, and healthy controls. Paragraphs 0143 and 0145 further describe using a previously selected knowledge base group. Thus, it appears that, in order to provide an invention which is capable of diagnosing any solid tumor from hemodynamic response patterns, a knowledge base must be created which contains correlations of hemodynamic response patterns derived from application of a specific electromagnetic probe. Examiner is unaware of a working example of universal solid tumor cancer diagnosis via such electromagnetic signal response analysis. Examiner considers such a task to constitute undue quantity of experimentation.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JUSTIN XU whose telephone number is (571)272-6617. The examiner can normally be reached Mon-Fri 7:30-5:00.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Alexander Valvis can be reached at (571) 272-4233. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JUSTIN XU/ Primary Examiner, Art Unit 3791